Skip to main content

Table 2 Availability of the asthma-COPD drugs in the 4 study regions

From: Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective

  Availability (%)
Selected medicines (N = 10 classes and 2 types of spacers) Central region Eastern region Western region Northern region P value
Inhaled LABA and LAAC combinations 0.0 0.0 0.0 0.0 NA
Inhaled LAAC monotherapies 0.0 0.0 0.0 0.0 NA
Inhaled LABA monotherapies 9.7 4.2 4.6 33.3 0.031
Inhaled SABA and SAAC combinations 19.4 0.0 0.0 0.0 0.005
Inhaled SAAC monotherapy 22.2 0.0 0.0 0.0 0.002
Oral methylxanthines 22.2 16.7 4.6 8.3 0.215
Adult spacer devices 25.0 8.3 13.6 8.3 0.184
Paediatric spacer devices 30.6 4.2 4.6 8.3 0.004
Inhaled LABA-ICS combinations 61.1 25.0 31.8 33.3 0.004
ICS monotherapies 61.1 37.5 9.1 33.3 <0.001
Oral LTRA 75.0 37.5 50.0 41.7 0.002
Inhaled SABA monotherapy 80.6 70.8 68.2 66.7 0.490
  1. LAMA-Long acting anti muscarinic agents, LABA-Long acting beta agonists, SABA-Short acting beta agonists, SAMA-Short acting anti muscarinic agents, ICS-Inhaled corticosteroids, LTRA-Leukotriene receptor antagonists